|1.||Butterworth, Roger F: 3 articles (01/2014 - 12/2002)|
|2.||Rahimi, Robert S: 2 articles (05/2013 - 05/2012)|
|3.||Rockey, Don C: 2 articles (05/2013 - 05/2012)|
|4.||Ndraha, Suzanna: 2 articles (01/2011 - 07/2010)|
|5.||Simadibrata, Marcellus: 2 articles (01/2011 - 07/2010)|
|6.||Jayalekshmi, H: 2 articles (01/2009 - 10/2005)|
|7.||Hass, H G: 2 articles (10/2006 - 04/2005)|
|8.||Kaiser, S: 2 articles (10/2006 - 04/2005)|
|9.||Butterworth, R F: 2 articles (12/2003 - 12/2001)|
|10.||Shi, K-Q: 1 article (04/2015)|
11/01/2008 - "L-ornithine-L-aspartate infusions were found to be effective in cirrhotic patients with hepatic encephalopathy."
06/01/2005 - "L-ornithine-L-aspartate is effective for hepatic encephalopathy and has not obvious side effect."
06/01/1998 - "L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action."
05/01/1998 - "Also, the mental state grade (p<0.05) and the Portosystemic Encephalopathy Index (p<0.01), improved to a much greater degree in the L-ornithine-L-aspartate group than in the placebo group. "
11/01/2011 - "To evaluate the efficacy of L-ornithine-L-aspartate (LOLA) as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy (HE). "
04/01/2010 - "A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis."
05/01/1998 - "Oral L-ornithine-L-aspartate is a safe, well-tolerated treatment with a good compliance rate and a beneficial therapeutic effect in patients with cirrhosis and stable, overt, chronic hepatic encephalopathy."
06/01/1997 - "Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study."
05/01/2013 - "l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials."
03/12/2013 - "As proof of principle, 22 patients with well-compensated, biopsy-proven cirrhosis of differing etiology and previous minimal hepatic encephalopathy were treated with oral l-ornithine l-aspartate for 4 weeks. "
03/15/1989 - "Ornithine-aspartate in hyperammonemia--results of a study]."
12/01/2002 - "The clinical efficacy of both oral and parenteral L-ornithine-L-aspartate (OA) was confirmed by randomized, placebo-controlled, double-blind studies in patients with manifest hepatic encephalopathy and hyperammonemia. "
10/01/1997 - "CCl4-induced cirrhosis of rats was used for studying the influence of L-ornithine-L-aspartate (OA) on hyperammonemia. "
01/01/1997 - "L-ornithine vs. L-ornithine-L-aspartate as a treatment for hyperammonemia-induced encephalopathy in rats."
11/01/1993 - "This paper documents dose-dependent effects of ornithine aspartate (OA) on postprandial hyperammonemia and plasma amino acids. "
|4.||End Stage Liver Disease
01/01/2011 - "[Study on L-Ornithine-L-Aspartate in the treatment of acute-on-chronic liver failure]."
09/01/1999 - "As part of a series of studies to evaluate the therapeutic efficacy of ammonia-lowering agents, groups of rats with ALF caused by hepatic devascularization were treated with L-ornithine-L-aspartate (OA), an agent shown previously to be effective in reducing blood ammonia concentrations in both experimental and human chronic liver failure. "
|5.||Acute Liver Failure (Fulminant Hepatic Failure)
06/01/2009 - "Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study."
09/01/1999 - "L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure."
12/01/2001 - "Therapeutic measures currently used to prevent and treat brain edema and encephalopathy in patients with acute liver failure include mild hypothermia and the ammonia-lowering agent L-ornithine-L-aspartate."
|3.||RNA (Ribonucleic Acid)
|7.||Anti-Bacterial Agents (Antibiotics)
|9.||Branched-Chain Amino Acids
|2.||Protein-Restricted Diet (Diet, Protein Restricted)
|4.||Chelation Therapy (Therapy, Chelation)